Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.38 |
| ▸ | TYMP | P19971 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | PAK4 | O96013 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
| ▸ | PRKACA | P17612 | 1/20 | 0.31 |
| ▸ | FLT1 | P17948 | 1/20 | 0.31 |
| ▸ | LTK | P29376 | 1/20 | 0.31 |
| ▸ | GRK5 | P34947 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL5827353 | 0.63 | — | — | |
| SCHEMBL22164629 | 0.59 | TYMP (0.35) | PNPTYMP | |
| SCHEMBL22147446 | 0.54 | — | — | |
| SCHEMBL12191404 | 0.54 | DYRK1A (0.35) | TYMPDYRK1A | |
| SCHEMBL868785 | 0.54 | RET (0.39) | ABL1RETDYRK1ALRRK2AURKB | |
| SCHEMBL16200056 | 0.53 | — | — | |
| SCHEMBL31641924 | 0.53 | — | — | |
| SCHEMBL10692506 | 0.51 | — | — | |
| SCHEMBL11834767 | 0.50 | LMNA (0.43) | DYRK1A | |
| SCHEMBL31634339 | 0.50 | LMNA (0.43) | DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729518-A1 | CRYSTAL FORM OF METHIONINE ADENOSYLTRANSFERASE 2A HETEROCYCLIC INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (CN) | 2026-04-22 | — | — | EP | disclosed |
| CN-121586715-A | Salt and crystal forms of methionine adenosine transferase 2A heterocyclic inhibitor and preparation method thereof | 南京正大天晴制药有限公司 | 2026-02-27 | — | — | CN | disclosed |
| US-20250186444-A1 | METHIONINE ADENOSYLTRANSFERASE 2A HETEROCYCLIC INHIBITOR | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2025-06-12 | — | — | US | disclosed |
| WO-2024255802-A1 | SALT AND CRYSTAL FORM OF METHIONINE ADENOSYLTRANSFERASE-2A HETEROCYCLIC INHIBITOR, AND PREPARATION METHOD THEREFOR | 南京正大天晴制药有限公司 | 2024-12-19 | — | — | WO | disclosed |
| WO-2024255805-A1 | CRYSTAL FORM OF METHIONINE ADENOSYLTRANSFERASE 2A HETEROCYCLIC INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 南京正大天晴制药有限公司 | 2024-12-19 | — | — | WO | disclosed |
| EP-4434989-A1 | METHIONINE ADENOSYLTRANSFERASE 2A HETEROCYCLIC INHIBITOR | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (CN) | 2024-09-25 | — | — | EP | disclosed |
| CN-118414338-A | Heterocyclic inhibitors of methionine adenosyltransferase 2A | 南京正大天晴制药有限公司 | 2024-07-30 | — | — | CN | disclosed |
| WO-2023116696-A1 | METHIONINE ADENOSYLTRANSFERASE 2A HETEROCYCLIC INHIBITOR | 南京正大天晴制药有限公司 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023116696-A1 | METHIONINE ADENOSYLTRANSFERASE 2A HETEROCYCLIC INHIBITOR | 南京正大天晴制药有限公司 | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186444-A1 | METHIONINE ADENOSYLTRANSFERASE 2A HETEROCYCLIC INHIBITOR | MAT2B, MAT2A, MAT1A | PNP 278/4885TYMP 88/4885CHEK1 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.